Kangtai Biotech: Announcement on preparations for asset impairment accrued for the semi-annual period of 2024
Kangtai Biotech: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Kangtai Biotech: Announcement on progress of wholly-owned subsidiaries providing guarantees to the company
Shenzhen Kangtai Biological Products: Announcement on the acceptance of clinical trial application for the quadrivalent influenza virus split vaccine (MDCK cell) of the company.
Shenzhen Kangtai Biological Products: Announcement of interest payment for convertible bonds of the company due in 2024.
Shenzhen Kangtai Biological Products: Announcement of convertible bond conversion into stocks for the second quarter of 2024.
Shenzhen Kangtai Biological Products: Announcement Regarding the Potential Triggering of Conversion Price Adjustment Conditions for Kangtai Convertible Bonds
Shenzhen Kangtai Biological Products: 2021 Shenzhen Kangtai Biological Products Co., Ltd. issued convertible bonds on the Growth to unspecified objects. The 2024 tracking rating report of the CSI Enterprise Bond Index.
Shenzhen Kangtai Biological Products: Shenzhen Kangtai Biological Products Co., Ltd. issued a trust management report on convertible corporate bonds (2023) to unspecified parties.
Shenzhen Kangtai Biological Products: Shenzhen Kangtai Biological Products Co., Ltd. issued a third interim entrusted management report on convertible corporate bonds to unspecified persons (2024 annual report).
Shenzhen Kangtai Biological Products: Announcement regarding the price adjustment of convertible bond-to-stock conversion.
Shenzhen Kangtai Biological Products: Shenzhen Kangtai Biological Products Co., Ltd. issued a second temporary trustee management report (2024) for convertible corporate bonds to unspecified parties.
Shenzhen Kangtai Biological Products: Announcement on the downward revision of the conversion price of convertible corporate bonds
Shenzhen Kangtai Biological Products: Legal Opinion of Guohao Lawyers (Shenzhen) Firm on the 2023 Annual General Meeting of Shareholders of Shenzhen Kangtai Biological Products Co., Ltd.
Shenzhen Kangtai Biological Products: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Shenzhen Kangtai Biological Products: Notice on the change of office address
Shenzhen Kangtai Biological Products: Announcement on the acceptance of clinical trial applications for the company's quadrivalent influenza virus lysis vaccine for people aged 6-35 months
Shenzhen Kangtai Biological Products: Announcement on the board of directors proposing to revise the conversion price of convertible corporate bonds downward
Shenzhen Kangtai Biological Products: Announcement on adding the provisional proposal for the 2023 Annual General Meeting of Shareholders and the Supplementary Notice of the Shareholders' Meeting
Shenzhen Kangtai Biological Products: Shareholder return plan for the next three years (2024-2026)
No Data